Drug intelligence / Profile preview

AMP-203 + AMP-506

Development stage: Preclinical
Lead developer: Amplifica Holdings Group
Modality: Recombinant Proteins and Enzymes
Administration: Intradermal

Overview

AMP-203 + AMP-506 is a preclinical injectable therapeutic combination being developed by Amplifica Studio for the treatment of androgenetic alopecia (hair loss). The program is based on the research of Dr. Maksim Plikus, who identified osteopontin as a key signaling molecule that drives excessive hair growth in hairy moles and induces hair follicle reactivation. AMP-203 is an osteopontin-based compound, while AMP-506 is a companion molecule administered alongside it to enhance or support its activity. The treatment is delivered via intradermal injection to stimulate dormant hair follicles.

Other names: AMP-203 / AMP-506

Targets

CD44 (CD44 antigen)

Beyond the preview

Go deeper on AMP-203 + AMP-506.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMP-203 + AMP-506.

Explore the full profile